The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
1. Following our earlier observations that the tachykinin NK1 receptor antagonist CP-99,994 is an effective anti-emetic in ferrets, we have examined the anti-emetic effects of a more potent and novel NK1 receptor antagonist, GR203040, against various emetic stimuli in the ferret, dog and house musk...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1995
|
| _version_ | 1826259448882003968 |
|---|---|
| author | Gardner, C Twissell, D Dale, T Gale, J Jordan, C Kilpatrick, G Bountra, C Ward, P |
| author_facet | Gardner, C Twissell, D Dale, T Gale, J Jordan, C Kilpatrick, G Bountra, C Ward, P |
| author_sort | Gardner, C |
| collection | OXFORD |
| description | 1. Following our earlier observations that the tachykinin NK1 receptor antagonist CP-99,994 is an effective anti-emetic in ferrets, we have examined the anti-emetic effects of a more potent and novel NK1 receptor antagonist, GR203040, against various emetic stimuli in the ferret, dog and house musk shrew (Suncus murinus). 2. In ferrets, GR203040 (0.1 mg kg-1 s.c. or i.v.) is effective against emesis induced by radiation, cisplatin, cyclophosphamide, copper sulphate, ipecacuanha or morphine. 3. In animals in which emesis had been established with cisplatin, GR203040 (1 mg kg-1 s.c.) was fully effective as an interventional treatment. No further emesis was seen in animals treated with GR203040 whilst saline-treated animals continued to vomit. 4. GR203040 (0.1 mg kg-1 s.c.) retains anti-emetic efficacy in the ferret, even when given as a 6 h pretreatment, indicating that this compound has a long duration of action. The compound is also effective orally at the same dose, when given as a 90 min pretreatment. 5. GR203040 (0.1 mg kg-1 i.v.) is fully effective against ipecacuanha-induced emesis in the dog. 6. GR203040 is effective against motion- and cisplatin-induced emesis in Suncus murinus. These effects were seen at doses an order of magnitude greater than those shown to be effective against cisplatin in the ferret. 7. In conclusion, GR203040 is a novel anti-emetic agent, and the broad spectrum of anti-emetic activity, together with activity observed in three species, suggests that this compound is worthy of clinical investigation. |
| first_indexed | 2024-03-06T18:50:03Z |
| format | Journal article |
| id | oxford-uuid:0feb2bae-6aa0-400a-afb1-4bcc3e6d5a36 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:50:03Z |
| publishDate | 1995 |
| record_format | dspace |
| spelling | oxford-uuid:0feb2bae-6aa0-400a-afb1-4bcc3e6d5a362022-03-26T09:53:41ZThe broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0feb2bae-6aa0-400a-afb1-4bcc3e6d5a36EnglishSymplectic Elements at Oxford1995Gardner, CTwissell, DDale, TGale, JJordan, CKilpatrick, GBountra, CWard, P1. Following our earlier observations that the tachykinin NK1 receptor antagonist CP-99,994 is an effective anti-emetic in ferrets, we have examined the anti-emetic effects of a more potent and novel NK1 receptor antagonist, GR203040, against various emetic stimuli in the ferret, dog and house musk shrew (Suncus murinus). 2. In ferrets, GR203040 (0.1 mg kg-1 s.c. or i.v.) is effective against emesis induced by radiation, cisplatin, cyclophosphamide, copper sulphate, ipecacuanha or morphine. 3. In animals in which emesis had been established with cisplatin, GR203040 (1 mg kg-1 s.c.) was fully effective as an interventional treatment. No further emesis was seen in animals treated with GR203040 whilst saline-treated animals continued to vomit. 4. GR203040 (0.1 mg kg-1 s.c.) retains anti-emetic efficacy in the ferret, even when given as a 6 h pretreatment, indicating that this compound has a long duration of action. The compound is also effective orally at the same dose, when given as a 90 min pretreatment. 5. GR203040 (0.1 mg kg-1 i.v.) is fully effective against ipecacuanha-induced emesis in the dog. 6. GR203040 is effective against motion- and cisplatin-induced emesis in Suncus murinus. These effects were seen at doses an order of magnitude greater than those shown to be effective against cisplatin in the ferret. 7. In conclusion, GR203040 is a novel anti-emetic agent, and the broad spectrum of anti-emetic activity, together with activity observed in three species, suggests that this compound is worthy of clinical investigation. |
| spellingShingle | Gardner, C Twissell, D Dale, T Gale, J Jordan, C Kilpatrick, G Bountra, C Ward, P The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title_full | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title_fullStr | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title_full_unstemmed | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title_short | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. |
| title_sort | broad spectrum anti emetic activity of the novel non peptide tachykinin nk1 receptor antagonist gr203040 |
| work_keys_str_mv | AT gardnerc thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT twisselld thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT dalet thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT galej thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT jordanc thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT kilpatrickg thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT bountrac thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT wardp thebroadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT gardnerc broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT twisselld broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT dalet broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT galej broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT jordanc broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT kilpatrickg broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT bountrac broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 AT wardp broadspectrumantiemeticactivityofthenovelnonpeptidetachykininnk1receptorantagonistgr203040 |